WO2018062800A1 - Composition anti-stress contenant de l'esculine - Google Patents

Composition anti-stress contenant de l'esculine Download PDF

Info

Publication number
WO2018062800A1
WO2018062800A1 PCT/KR2017/010585 KR2017010585W WO2018062800A1 WO 2018062800 A1 WO2018062800 A1 WO 2018062800A1 KR 2017010585 W KR2017010585 W KR 2017010585W WO 2018062800 A1 WO2018062800 A1 WO 2018062800A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
acid
stress
esculin
present
Prior art date
Application number
PCT/KR2017/010585
Other languages
English (en)
Korean (ko)
Inventor
김주원
최민식
홍용덕
조시영
Original Assignee
(주)아모레퍼시픽
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by (주)아모레퍼시픽 filed Critical (주)아모레퍼시픽
Publication of WO2018062800A1 publication Critical patent/WO2018062800A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A61K8/602—Glycosides, e.g. rutin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/322—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the nervous system or on mental function
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00—Food ingredients
    • A23V2250/60—Sugars, e.g. mono-, di-, tri-, tetra-saccharides

Definitions

  • antistress compositions comprising esculin, isomers thereof, pharmaceutically or cosmetically acceptable salts thereof, hydrates thereof or solvates thereof.
  • Stress which indicates maladjustment of the human body due to external stimuli or environmental changes, may cause hyperactivation of the sympathetic nervous system, resulting in transient or persistent psychological and physical reactions. Modern people are exposed to various stress sources, which are closely related to changes in various mental and physical conditions, which raises interest in resistance to stress.
  • Antidepressant stress therapeutic agents using synthetic compounds can cause side effects and human toxicity, and there is a need for substances that exhibit antistress effects using natural products as cosmetics or foods, not as drugs.
  • the problem to be solved by the present invention is to provide a composition exhibiting an effect of improving the stress resistance.
  • the problem to be solved by the present invention is to provide a composition that exhibits the effect of improving stress resistance without human toxicity using natural products.
  • the problem to be solved by the present invention is to provide a composition excellent in resistance to glucocorticoid hormone-induced stress.
  • the problem to be solved by the present invention is to provide a composition that can improve the stress resistance through the activation of the oxytocin receptor.
  • the problem to be solved by the present invention is to provide a composition for alleviating or improving physical symptoms caused by stress.
  • the problem to be solved by the present invention is to provide a composition for alleviating or improving the psychological symptoms caused by stress.
  • the present invention provides an antistress composition
  • an antistress composition comprising esculin, an isomer thereof, a pharmaceutically or cosmetically acceptable salt thereof, a hydrate thereof, or a solvate thereof as an active ingredient.
  • the present invention can exhibit a stress resistance improving effect.
  • the present invention can exhibit the effect of improving stress resistance without natural toxicity using natural products.
  • the present invention may be excellent resistance to glucocorticoid hormone-induced stress.
  • the present invention can improve stress resistance through activation of the oxytocin receptor.
  • the present invention can alleviate or ameliorate physical symptoms caused by stress.
  • the present invention may alleviate or ameliorate psychological symptoms caused by stress.
  • 1 is a graph confirming the binding of esculin to the oxytocin receptor.
  • 2 is a graph confirming the inhibitory effect of glucocorticoid-induced cell death of esculin.
  • isomers in particular are not only optical isomers (eg, essentially pure enantiomers, essentially pure diastereomers or mixtures thereof), but also form isomers ( conformation isomers (ie, isomers that differ only by their angles of one or more chemical bonds), position isomers (especially tautomers) or geometric isomers (eg, cis-trans isomers) do.
  • essentially pure means at least about 90%, preferably at least about 95%, of a specific compound, for example enantiomers or diastereomers, when used in connection with an enantiomer or diastereomer. More preferably at least about 97% or at least about 98%, even more preferably at least about 99%, even more preferably at least about 99.5% (w / w).
  • pharmaceutically acceptable means the approval of a government or equivalent regulatory body to use in animals, more specifically in humans, by avoiding significant toxic effects when used in conventional medicinal dosages. It can be received or approved, or listed in a pharmacopoeia or recognized as another general pharmacopeia.
  • salt means a salt according to one aspect of the invention that is pharmaceutically or cosmetically acceptable and has the desired pharmacological activity of the parent compound.
  • the salt is formed from (1) an inorganic acid such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, or the like; Or acetic acid, propionic acid, hexanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, 3- (4-hydroxybenzoyl) Benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, 1,2-ethane-disulfonic acid, 2-hydroxyethanesulfonic acid, benzenesulfonic acid, 4-ch
  • hydrate refers to a compound to which water is bound, and is a broad concept including an inclusion compound having no chemical bonding force between water and the compound.
  • solvate means a higher order compound produced between molecules or ions of a solute and molecules or ions of a solvent.
  • an antistress composition comprising esculin, an isomer thereof, a pharmaceutically or cosmetically acceptable salt thereof, a hydrate thereof, or a solvate thereof as an active ingredient.
  • the esculin is a compound having a structure represented by the following formula.
  • the esculin is known as a substance that affects blood circulation improvement and vascular health, but the present inventors have found that esculin has an effect of improving stress resistance. Therefore, the composition according to the present embodiment may exhibit excellent effects as a composition for antistress.
  • the composition is resistant to glucocorticoid-based hormone-induced stress.
  • the composition may inhibit cell death induced by glucocorticoid hormone. Through the inhibition of apoptosis induced by the glucocorticoid-based hormones may exhibit an alleviation or improvement of psychological or physical symptoms.
  • the glucocorticoid hormone may include one or more selected from cortisol, cortisone, and corticosterone.
  • the composition may bind to the oxytocin receptor to activate the oxytocin receptor.
  • Oxytocin (Oxytocin, OXT, OT) is a neurotransmitter secreted by the pituitary gland of various animals, including vertebrates and invertebrates, commonly referred to as uterine contraction hormone. Oxytocin is involved in the contraction of the uterus at birth and is known to be released into the bloodstream from the pituitary gland, even when looking at crushing partners. In addition, the effects of oxytocin on stress relaxation and social effects have been reported.
  • the composition according to the present embodiment may exhibit stress resistance through activation of the oxytocin receptor.
  • the composition may relieve or ameliorate physical symptoms caused by stress.
  • physical symptoms caused by stress include irritable colitis, indigestion, gastritis, stomach cramps, gastroduodenal ulcers, digestive symptoms such as constipation, nervous system symptoms such as migraine, urinary symptoms such as erectile dysfunction, insensitivity, hypertension, angina, etc. Cardiovascular symptoms, hair loss, and skin symptoms such as hives. Such symptoms can develop into a disease due to constant stress.
  • the composition may relieve or ameliorate the psychological symptoms caused by stress.
  • Examples of the psychological symptoms may include depression, anxiety disorder, insomnia, and nervousness.
  • the composition may be a cosmetic composition.
  • the cosmetic composition according to the embodiment of the present invention may include 0.0001% by weight to 99% by weight, for example 0.01% by weight to 60% by weight, based on the total weight of the composition, but is not limited thereto.
  • Cosmetic compositions according to embodiments of the present invention may be formulated containing a cosmetically or dermatologically acceptable medium or base. It is any formulation suitable for topical application, in the form of suspensions, microemulsions, microcapsules, microgranules or ionic (liposomal) and nonionic vesicle dispersants or creams, skins, lotions, powders, ointments, sprays or concealers. It may be provided in the form of a stick. It may also be used in the form of a foam or in the form of an aerosol composition further containing a compressed propellant. These compositions can be prepared according to conventional methods in the art.
  • the cosmetic composition according to the embodiments of the present invention may be a powder, a fatty substance, an organic solvent, a dissolving agent, a thickening agent, a gelling agent, a softening agent, an antioxidant, a suspending agent, a stabilizer, a foaming agent, a fragrance, a surfactant.
  • ionic or nonionic emulsifiers fillers, metal ion sequestrants, chelating agents, preservatives, vitamins, blockers, wetting agents, essential oils, dyes, pigments, hydrophilic or lipophilic active agents, lipid vesicles or cosmetics It may contain adjuvants conventionally used in the cosmetic or dermatological fields, such as any other ingredients used. Such adjuvants are introduced in amounts generally used in the cosmetic or dermatological arts.
  • the cosmetic composition according to the embodiments of the present invention may further contain a skin absorption promoting substance to increase the skin improving effect.
  • compositions according to embodiments of the present invention may be provided in various forms of food additives or functional foods containing the active ingredient. It can be processed into fermented milk, cheese, yogurt, juice, probiotic and health food, including the active ingredient, and can be used in the form of various other food additives.
  • composition according to the embodiments of the present invention may be a composition for health food.
  • the health food composition according to the embodiment of the present invention may include 0.0001% by weight to 99% by weight, for example, 0.01% by weight to 60% by weight, based on the total weight of the composition, but is not limited thereto.
  • the health food composition may be formulated as pills, capsules, tablets, granules, caramels or drinks. In other embodiments, it may be processed in the form of a liquid, powder, granules, tablets or tea bags and the like.
  • composition may be administered by various methods, such as simple drinking, injection, spray or squeeze.
  • the composition may contain other ingredients and the like that can give a synergistic effect to the main effect within a range that does not impair the main effect of the present invention.
  • it may further include additives such as perfumes, pigments, fungicides, antioxidants, preservatives, moisturizers, thickeners, inorganic salts, emulsifiers and synthetic polymer materials to improve physical properties.
  • additives such as perfumes, pigments, fungicides, antioxidants, preservatives, moisturizers, thickeners, inorganic salts, emulsifiers and synthetic polymer materials to improve physical properties.
  • supplementary ingredients such as water soluble vitamins, oil soluble vitamins, polymer peptides, polymer polysaccharides and seaweed extract may be further included.
  • ingredients may be suitably selected and formulated by those skilled in the art according to the dosage form or purpose of use, and the amount thereof may be selected within a range that does not impair the object and effect of the present invention.
  • the amount of the components added may be 0.01 wt% to 5 wt%, for example, 0.01 wt% to 3 wt%, based on the total weight of the composition, but is not limited thereto.
  • an esculin hydrate (sigma) was applied to an SPR chip (Biorad, MA) on which an oxytocin receptor recombinant protein (Mybiosource, MA) was bound at 37 ° C. After reacting for 90 seconds by treating at a concentration of 0-400 ⁇ M, the binding pattern of esculin to oxytocin receptor was measured using a surface plasmon resonance (Biorad, MA), and the results are shown in FIG. 1. .
  • Test Example 2 Glucocorticoid-induced cell death inhibitory effect
  • PC12 neurocytoma cell; KCLB21721, Korea Cell Line Bank
  • PC12 neurocytoma cell; KCLB21721, Korea Cell Line Bank
  • Culture medium was prepared using RPMI 1640 (10% serum (FBS, Gibco), 100 U / ml penicillin (Gibco) and 100 ⁇ g / ml streptomycin (Gibco). Gibco BRL, Grand Island, NY, USA)) media.
  • the stress hormone corticosterone corticosterone, sigma, MA
  • composition shown in the following table was prepared in the conventional method for the flexible cosmetic.
  • a hair lotion is prepared according to a conventional method with the composition described in the table below.
  • a shampoo composition was prepared according to a conventional method with the compositions described in the table below.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Birds (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne une composition anti-stress contenant de l'esculine, un isomère de celle-ci, un sel pharmaceutiquement ou cosmétiquement acceptable de celle-ci, un hydrate de celle-ci ou un solvate de celle-ci utilisé comme principe actif. La composition peut atténuer ou soulager les symptômes physiques et psychologiques induits par le stress.
PCT/KR2017/010585 2016-09-27 2017-09-26 Composition anti-stress contenant de l'esculine WO2018062800A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020160124252A KR20180034123A (ko) 2016-09-27 2016-09-27 에스쿨린을 포함하는 항스트레스 조성물
KR10-2016-0124252 2016-09-27

Publications (1)

Publication Number Publication Date
WO2018062800A1 true WO2018062800A1 (fr) 2018-04-05

Family

ID=61759823

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2017/010585 WO2018062800A1 (fr) 2016-09-27 2017-09-26 Composition anti-stress contenant de l'esculine

Country Status (2)

Country Link
KR (1) KR20180034123A (fr)
WO (1) WO2018062800A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102002168B1 (ko) * 2018-03-23 2019-07-23 한국 한의학 연구원 에스쿨린을 유효성분으로 포함하는 우울증 및 불안장애의 예방, 개선 또는 치료용 조성물

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101129394A (zh) * 2006-08-21 2008-02-27 中国医学科学院药物研究所 秦皮甲素预防和/或治疗心脑血管疾病的新用途
KR20130025074A (ko) * 2011-09-01 2013-03-11 (주)아모레퍼시픽 에스쿨린 유도체를 포함하는 피부 미백용 조성물
KR20130125745A (ko) * 2013-11-05 2013-11-19 한국과학기술연구원 에스쿨린을 포함하는 조성물

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101129394A (zh) * 2006-08-21 2008-02-27 中国医学科学院药物研究所 秦皮甲素预防和/或治疗心脑血管疾病的新用途
KR20130025074A (ko) * 2011-09-01 2013-03-11 (주)아모레퍼시픽 에스쿨린 유도체를 포함하는 피부 미백용 조성물
KR20130125745A (ko) * 2013-11-05 2013-11-19 한국과학기술연구원 에스쿨린을 포함하는 조성물

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MARTIN, M. J. ET AL.: "Esculine, Ranitidine and Carbenoxolone: Different Modes of Action on Gastric Mucosa", GENERAL PHARMACOLOGY, vol. 22, no. 6, 1991, pages 1001 - 1004, XP023834179 *
RIOS, E. R. V. ET AL.: "Mechanisms Involved in the Gastroprotective Activity of Esculin on Acute Gastric Lesions in Mice", CHEMICO-BIOLOGICAL INTERACTIONS, vol. 188, 2010, pages 246 - 254, XP027247425 *

Also Published As

Publication number Publication date
KR20180034123A (ko) 2018-04-04

Similar Documents

Publication Publication Date Title
WO2018139898A1 (fr) Composition destinée à renforcer l'immunité, contenant des polysaccharides de baie de ginseng
WO2015002393A1 (fr) Composition de traitement ou de prévention d'une maladie cutanée inflammatoire comprenant, comme ingrédient actif, un extrait d'agrumes immatures ou de la synéphrine, ou leur sel
CA2757437A1 (fr) Compositions et procedes pour une immunotherapie
WO2021201532A1 (fr) Composition de prévention, de soulagement ou de traitement du syndrome ménopausique chez la femme, contenant un extrait de rosa rugosa en tant que principe actif
WO2017014502A1 (fr) Composition pharmaceutique pour la prévention ou le traitement de maladies médiées par il-6 comprenant un extrait de fleur de rosa rugosa en tant que substance active
WO2018062801A1 (fr) Composition anti-stress contenant de la cosmopérine
JP3968405B2 (ja) 抗アレルギー剤
EP0749753B1 (fr) Utilisation d'une poudre ou d'un extrait de guava pour le traitement des maladies allergiques
WO2018203668A1 (fr) Composition de préparation cutanée à usage externe destinée à soulager une peau atopique et produit cosmétique la contenant
WO2017191856A1 (fr) Effet antidiabétique du gypénoside 75
WO2020040432A1 (fr) Composition pharmaceutique pour prévenir ou traiter des maladies musculaires, contenant un extrait de baie de ginseng en tant que principe actif
WO2018062800A1 (fr) Composition anti-stress contenant de l'esculine
WO2020096127A1 (fr) Composition comprenant une éponge hydrolysée destinée à soulager l'arthralgie ou la myalgie
KR102488131B1 (ko) 유산균 쌀 발효물을 포함하는 피부 마이크로비옴 기능 증진용 조성물
WO2018062765A1 (fr) Composition anti-stress contenant du magnolol
WO2010134769A2 (fr) Composition de prévention ou de traitement du syndrome du côlon irritable
WO2015034247A1 (fr) Composition contenant un composé de monoacétyldiacylglycérol comme principe actif pour prévenir ou traiter la dermatite atopique
WO2018062764A1 (fr) Composition anti-stress contenant du honokiol
KR20230039856A (ko) 복합 진세노사이드 조성물을 포함하는 항염증 조성물
WO2019031655A1 (fr) Composition comprenant du thymol comme principe actif pour prévenir ou traiter les rides de la peau ou la dermatite atopique
KR101273027B1 (ko) 캄페롤을 유효성분으로 함유하는 피지 분비 억제용 및항비만용 조성물
RU2513580C1 (ru) Средство для лечения аритмии сердца
KR102137144B1 (ko) 피라칸타 잎 추출물을 포함하는 항염증용 조성물
WO2010128788A2 (fr) Compositions anti-obésité constituées d'agents pour application cutanée et contenant la capsaïcine ou des composés analogues à la capsaïcine comme ingrédients actifs
WO2021187679A1 (fr) Composition comprenant un composé de saponine dérivé du concombre de mer pour prévenir, soulager ou traiter une neuropathie

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17856686

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17856686

Country of ref document: EP

Kind code of ref document: A1